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INTRODUCTION
Pericentric inversion of chromosome 9, inv(9)(p11q13), is
inherited as a non-pathogenic variation in normal popu-
lation (0.8—2%); however, this variation is also reported to
be associated with predisposition to the development of
solid tumors or acute leukemias (ALs). Keung et al. [1] reported
that the prevalence of constitutional inv(9) variation in
799 adult AL cases was similar to that observed in the
general population (0.8%). Huh et al. [2] reported that the
incidence of constitutional chromosomal aberration in
hematologic malignancies was similar to that of benign
hematologic disorders (2.4% and 2.8%, respectively), and
the inv(9) variation was frequently observed in both
groups. However, the association between constitutional
inv(9) variation and CML or ALL patients with Philadel-
phia (Ph) chromosome has been rarely documented [3].
To our knowledge, there have been no reports on the
association between CML and constitutional pericentric
inv(9) variation in any ethnic group. In this study, we
investigated the frequency and clinical features of Kore-
an CML patients with concomitant inv(9) and t(9;22).
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Background : Although the pericentric inversion of chromosome 9, inv(9)(p11q13), is generally
considered a normal variation, it is also associated with solid tumors and several hematologic
malignancies such as biphenotypic acute leukemia, ALL, AML, and myeloproliferative neoplasms.
However, to the best of our knowledge, there have been no reports that suggest an association
between CML and constitutional pericentric inversion of chromosome 9. The purpose of this retro-
spective study was to investigate the frequency and clinical features of CML patients with concomi-
tant inv(9) and t(9;22)(q34;q11.2) variation at our institution.
Methods : We reviewed the bone marrow chromosome database entries between October 2006
and December 2008 to identify patients with concomitant inv(9) and t(9;22) variations. Laboratory
and clinical data of the patients were obtained from the electronic medical record system.
Results : Among the 51 CML patients, 4 (7.8%) had concomitant inv(9) and t(9;22) variations.
Conclusions : Although the association between inv(9) variation and CML is still controversial, we
believe that hematologists should consider the role of constitutional inv(9) variation in CML patients
to avoid overlooking the impaired engraftment potential of hematopoietic stem cells harboring
inv(9). Therefore, we suggest that more effort should be invested to develop cytogenetic tests for
detecting constitutional inv(9) variation in CML patients. (Korean J Lab Med 2010;30:218-23)
Key Words : CML, Constitutional inv(9)
Received : June 10, 2009 Manuscript No : KJLM-09-070
Revision received : March 24, 2010
Accepted : April 27, 2010
Corresponding author : Jong Rak Choi, M.D.
Department of Laboratory Medicine, Yonsei University College
of Medicine, 250 Seongsan-ro, Seodaemun-gu, Seoul 120-752,
Korea
Tel : +82-2-2228-2445, Fax : +82-2-313-0956
E-mail : cjr0606@yuhs.ac
ISSN 1598-6535  The Korean Society for Laboratory Medicine 
Korean J Lab Med 2010;30:218-23
DOI 10.3343/kjlm.2010.30.3.218
Suh B, et al., Constitutional Inversion 9 in CML 219
MATERIALS AND METHODS
We retrospectively reviewed the bone marrow chro-
mosome database at the Severance Hospital of Yonsei
University (Seoul, Korea) between October 2006 and
December 2008. After selecting the Ph+ karyotypes, we
excluded the repeated results from the same patients
and identified cases with inv(9) variation among the Ph+
cases. Clinical and laboratory data were obtained by
reviewing the U-Severance electronic medical record
system.
RESULTS
Our database search revealed 103 Ph+ karyotypes.
After excluding repeated results from the same patients,
we identified 70 patients, including 51 patients of CML,
16 of ALL, and 3 of biphenotypic acute leukemia (BAL),
with a t(9;22)(q34;q11.2) variation or BCR/ABL1 rearrange-
ment. Among the 70 patients who underwent bone mar-
row and chromosome analysis, 4 CML patients had con-
comitant inv(9) and t(9;22) variation or BCR/ABL1 rear-
rangement. Among the other 19 Ph+ ALL or BAL patients,
none had a pericentric inversion in chromosome 9.
1. Patient 1
A 33-yr-old Korean man was admitted to the Sever-
ance Hospital with left upper quadrant discomfort in
June 2008. The initial complete blood count (CBC) results
showed Hb level of 9.1 g/dL; platelet count of 810,000/µL;
and white blood cell (WBC) count of 355,400/µL with 49%
segmental neutrophils, 1% lymphocytes, 19% myelocytes,
4% metamyelocytes, 14% band forms, 4% eosinophils, 4%
basophils, and 5% immature cells. Bone marrow aspira-
tion and biopsy analysis revealed a hypercellular marrow
with a significantly large number of granulocyte precur-
sors and megakaryocytes and a high myeloid/erythroid
(M/E) ratio (30:1). The initial chromosome analysis showed
the 46,XY,inv(9)(p11q13)c,t(9;22)(q34;q11.2) karyotype in all
20 metaphase cells (Fig. 1). FISH with BCR/ABL1 probe
(Abbott Molecular/Vysis, Des Plaines, IL, USA) revealed the
“nuc ish (ABL1×3),(BCR×3),(ABL1 con BCR×2)[91/252]/
(ABL1×2),(BCR×2),(ABL1 con BCR×1)[29/252]/(ABL1×
2),(BCR × 3),(ABL1 con BCR × 2)[15/252]”karyotype,
which was consistent with the abnormal pattern (1 or 2
fusions) in 53.6% of the nuclei examined. Gene rear-
rangement analysis was positive for BCR/ABL1 (b3a2
type) (Fig. 2). The patient was receiving imatinib mesy-
Fig. 1. The full karyogram of bone marrow cells of patient 1 is as follows: 46,XY,inv(9)(p11q13)c,t(9;22)(q34;q11.2). The bold arrow denotes
inv(9)(p11q13) and the single arrows denote t(9;22)(q34;q11.2).
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late (IM) after initial diagnosis, but we had to stop the
IM therapy after 1 month due to thrombocytopenia. His
follow-up bone marrow examination revealed 20—30%
cellularity without hematologic relapse of CML. Howev-
er, his second chromosome analysis still revealed the
46,XY,inv(9)(p11q13)c,t(9;22)(q34;q11.2) karyotype in 19
out of 20 analyzed cells.
2. Patient 2
A 64-yr-old man with a history of CML since July
2007 was brought to our hospital with fever and skin
rashes for 3 days. He was first diagnosed with CML and
treated with IM for 7 months. His CBC on arrival (Febru-
ary 2008) showed Hb level of 7.4 g/dL, platelet count of
10,000/µL, and WBC count of 550/µL. Bone marrow biopsy
examination showed a hypocellular marrow. M/E ratio was
not evaluated due to the paucity of hematopoietic cells.
The karyotype of all 20 G-banded marrow metaphase cells
was 46,XY,inv(9)(p11q13)c (Fig. 3). However, FISH with
BCR/ABL1probe (Abbott Molecular/Vysis) revealed the “nuc
ish (ABL1×3),(BCR×3),(ABL1 con BCR×2)[102/300]”
karyotype, which was consistent with the abnormal signal
patterns observed in 34.0% of the examined nuclei. In addition,
gene rearrangement analysis revealed a b2a2 type BCR/ABL1
rearrangement. After 1 month, he was discharged from our
hospital and referred to another regional institution.
3. Patient 3
A 45-yr-old man was brought to our hospital with
epigastric discomfort and leukocytosis in December 2008.
CBC showed Hb level of 10.1 g/dL; platelet count of 397,000/
µL; and WBC count of 106,700/µL with 68% segmental
neutrophils, 6% lymphocytes, 5% monocytes, 8% myelo-
cytes, 4% metamyelocytes, 8% band forms, and 1%
blasts. Bone marrow aspiration showed a hypercellular
marrow with a significantly large number of myeloid
precursors and megakaryocytes, which was consistent
with the diagnosis of CML. Chromosome analysis revealed
the 46,XY,inv(9)(p11q13)c,t(9;22)(q34;q11.2) karyotype in all
20 analyzed cells (Fig. 3). The FISH analysis for BCR/ABL1
showed a “nuc ish(ABL1×3),(BCR×3),(ABL1 con BCR×
2)[165/222]”karyotype. Gene rearrangement analysis for
BCR/ABL1 was positive (b2a2 type) (Fig. 2). After being
diagnosed with CML in chronic phase, he was discharged
Fig. 2. Multiplex reverse transcriptase-PCR (RT-PCR) was per-
formed using Seeplex Leukemia BCR/ABL kit (Seegene, Seoul,
Korea). Lane M, molecular marker provided by manufacturer; Lane
1, sample from Patient 1 (b3a2 type); Lane 2, negative control;
Lane 3, sample from Patient 3 (b2a2 type); Lane 4, positive control
(e1a2 type); Lane 5, RT-PCR product of b2a2/e1a2 as a positive
control; Lane 6, blank; Lane L, molecular size marker (100-bp lad-
der). Target and amplicon sizes are as follows: internal control (600
bp), b3a2 (476 bp), b2a2 (401 bp), and e1a2 (348 bp).
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Fig. 3. The partial karyogram of bone marrow cells of patients 2,
3, and 4. The bold arrows denote inv(9)(p11q13) and the single
arrows denote t(9;22)(q34;q11.2).
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Abbreviations: Ph+, Philadelphia positive; F, female; M, male.
Case
No.
Sex/Age/Country Diagnosis Karyotypes References
1 F/55/South Africa CML, aberrant translocation 46,XX,inv(9)(p1?2q11),t(9;22)(p1?2;q11)/46,XX,t(9;22),i(17)(q10) [7]
2 F/35/Korea CML 47,XX,dup(1)(q21q44),+6,inv(9)(p11q12),t(9;22)(q34;q11) [8]
3 F/55/Singapore ALL, B-lineage 45,XX,add(7)(p13),inv(9)(p11q13),t(9;22)(q34;q11),-21 [9]
4 M/7/Italy ALL, T-lineage 47,Y,del(X)(q21),del(3)(q23),del(5),inv(9)(p13q13)c,t(9;22)(q34;q11), [10]
add (10)(q26),+mar/47,idem,del(7)(p13)
5 M/4/United States ALL 71,XXY,+Y,inv(9)(p11q13),t(9;22)(q34;q11)x2,+10,-16,+21 [11]
6 F/26/United States Acute basophilic leukemia 46,XX,inv(9)(p11q13)c,t(9;22)(q34;q11)/46,XX,inv(9)c,t(9;22)(q13;q11) [12]
7 M/24/Korea CML 46,XY,inv(9)(p11q13)c,t(9;22)(q34;q11.2) [13]
8 M/52/Korea CML 46,XY,der(9)inv(9)(p11q13)ct(9;22)(q34;q11.2),der(22)t(9;22) [13]
9 M/33/Korea CML 46,XY,inv(9)(p11q13)c,t(9;22)(q34;q11.2) Present study
10 M/64/Korea CML 46,XY,inv(9)(p11q13)c Present study
11 M/45/Korea CML 46,XY,inv(9)(p11q13)c,t(9;22)(q34;q11.2) Present study
12 F/40/Korea CML 46,XX,inv(9)(p11q13)c,t(9;22)(q34;q11.2),i(17)(q10) Present study
Table 1. Reported cases of concomitant inv(9) and t(9;22) variations in Ph+ leukemia patients
and treated with hydroxyurea on an outpatient basis.
4. Patient 4
A 40-yr-old woman was diagnosed with CML in
chronic phase. Her chromosome analysis result in our
database showed a 46,XX,t(9;22)(q34;q11.2),i(17)(q10)
karyotype in 16 out of the 22 metaphase cells analyzed.
However, when we reviewed our chromosome database,
we detected an additional inv(9) variation in her karyo-
gram (Fig. 3). Therefore, the revised karyotype of this
patient was as follows: 46,XX,inv(9)(p11q13)c,t(9;22)
(q34;q11.2),i(17)(q10)[16]/46,XX,inv(9)(p11q13)c[6]. Despite
regular administration of IM, she developed neutropenic
fever and septic arthritis. We suspected IM resistance
because her condition deteriorated without any hemato-
logic response and discontinued the IM therapy. HLA-
matched transplantation was considered as an alterna-
tive treatment regimen.
DISCUSSION
There have been very few reports on the inv(9) varia-
tion as an acquired chromosomal abnormality in hema-
tologic malignancies [4, 5], and such variations are gen-
erally regarded as a constitutional abnormality with
familial inheritance. Keung et al. [1] have reported con-
stitutional pericentric inversion in chromosome 9 at a
frequency of 0.8-2% in normal population and at a sim-
ilar frequency in AL patients. Other studies reported lit-
tle difference in the incidences of constitutional chro-
mosome aberration between patients with hematologic
malignancies and the general population; however, this
may either be due to the low incidence of inv(9) [6-8] or
the exclusion of inv(9) [9]. Although the association
between inv(9) variation and CML is still a controversial
topic, constitutional pericentric inv(9) may be important for
predicting impaired engraftment potential of hematopoi-
etic stem cells harboring inv(9) [10, 11].
A careful review of literature and Mitelman database
revealed that concomitant inv(9) and t(9;22) variations
occurred sporadically in 8 patients [2, 3, 12-17], which
included 4 CML patients, 3 ALL patients, and 1 acute
basophilic leukemia patient (Table 1) [7-13]. In this study,
we analyzed the data of 70 Ph+ patients diagnosed with
CML, ALL, and BAL (51, 16, and 3 patients, respectively).
The inv(9) variation was not detected in any Ph+ ALL or
BAL patient, but it was detected at a relatively high fre-
quency (7.8%) in 4 out of 51 CML patients. The detection
of inv(9) is considered important in other hematologic
malignancies, including ALs [1, 18, 19]. However, there
have been very few studies on inv(9) detection in CML,
which indicates that this variation is either overlooked
or underestimated. In the fourth case in our study, we
222 Korean J Lab Med 2010;30:218-23
identified a previously undetected inv(9) variation as an
additional chromosomal abnormality during retrospec-
tive review. Other laboratories may similarly overlook
this variation partly due to neglect of its importance,
and underestimate the frequency of inv(9). In fact, in a
study investigating the association between constitution-
al chromosomal abnormality and hematologic malignan-
cy, the frequency of inv(9) in CML patients was observed
to be 2.6% (2/77) [2]. The discrepancies in the frequen-
cies may partly be due to the fact that the inv(9) varia-
tion confers an atypical chromosome morphology and
complicates karyotypic analysis. Further, because the
overall number of cases was limited in both the present
and previous studies, the difference in frequency may
not be significant [2]. More case studies are required for
further elucidation of the inv(9) prevalence and clinical
significance.
With rapid progress in pharmacogenetics, it is now
possible to develop tailored pharmacotherapy, even for
neoplastic diseases. IM has been used in tailored phar-
macotherapy for the treatment of CML, clonal hypere-
osinophilic disorder, gastrointestinal stromal tumor, etc.
Some patients develop resistance after IM therapy; how-
ever, this effect can be overcome with a standard dose or
high-dose imatinib therapy in most CML patients. For
patients with mutations that confer resistance to ima-
tinib, new generation tyrosine kinase inhibitors like nilo-
tinib and dasatinib may be effective. Thus far, no phar-
macologic therapy has been effective for mutations like
T315I, and stem cell transplantation is the only available
treatment option.
A majority of CML patients showed significant improve-
ment with the use of new tyrosine kinase inhibitors, but a
small fraction of patients manifested multiresistance to
these drugs. In such cases, additionally detected chromo-
somal abnormalities, whether acquired or constitutional,
may partly influence the success of drug therapy or trans-
plantation. We have suggested this possibility in the pre-
sent study and our previous report [20], and emphasized
the need for identifying additional chromosomal abnor-
malities in patients with drug resistance.
Being a retrospective analysis, the present study was
limited by a small number of patients of a single ethnic
group. Hence, we could not obtain data concerning fur-
ther prognosis of transplantation in CML patients with
inv(9). The underscoring finding of our study was that
the frequency of detecting constitutional pericentric
inv(9) in Korean CML patients was not lower than that
in normal population. This result suggested that consti-
tutional chromosomal abnormalities, including inv(9),
should be more cautiously in CML patients of not only
Korean population but of other ethnic groups as well. We
think that the prevalence of constitutional inv(9) variation
among CML patients is similar or slightly higher than
that in the general population, although further studies
in this regard are required. Therefore, on the basis of
the results of our study and literature review, we pro-
pose that cytogenetic analysis should involve detection
of constitutional inv(9) variation in CML patients.
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